PRP

About Propanc Biopharma

Propanc Biopharma is pioneering a proenzyme-based approach to combat metastatic cancer by targeting cancer stem cells, which are believed to be responsible for tumor recurrence and metastasis. Its lead asset, PRP, is in early clinical development for pancreatic and ovarian cancers. The company's strategy is to develop a first-in-class therapeutic that could prevent cancer from spreading and recurring, addressing a significant unmet medical need in oncology.

About Propanc Biopharma

Propanc Biopharma is pioneering a proenzyme-based approach to combat metastatic cancer by targeting cancer stem cells, which are believed to be responsible for tumor recurrence and metastasis. Its lead asset, PRP, is in early clinical development for pancreatic and ovarian cancers. The company's strategy is to develop a first-in-class therapeutic that could prevent cancer from spreading and recurring, addressing a significant unmet medical need in oncology.

Therapeutic Areas